Liver study tests how palovarotene behaves in impaired patients
NCT ID NCT06908954
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 study looked at how moderate and severe liver impairment changes the way the body handles a single dose of palovarotene, compared to healthy people. Thirty-one participants were split into three groups based on liver function and received up to 10 mg of the drug. Researchers measured drug levels in the blood and checked for side effects to understand dosing needs for liver-impaired patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
palovarotene
What this could lead to
If successful, this study could help doctors determine the right dose of palovarotene for people with liver problems, making the drug safer to use.
What could go wrong
This is a very early, small study (31 people) focused on drug processing, not on treating a disease. Results may not apply to real-world use or predict long-term safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Research Corporation/Texas Liver Institute
San Antonio, Texas, 78215, United States
-
ERG - Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Orlando Clinical Research Center
Orlando, Florida, 32809, United States
-
Pinnacle Clinical Research
San Antonio, Texas, 78229, United States